309 related articles for article (PubMed ID: 20412543)
1. A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.
Guo JJ; Pandey S; Doyle J; Bian B; Lis Y; Raisch DW
Value Health; 2010 Aug; 13(5):657-66. PubMed ID: 20412543
[TBL] [Abstract][Full Text] [Related]
2. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
Garrison LP; Towse A; Bresnahan BW
Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
[TBL] [Abstract][Full Text] [Related]
3. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
Leong J; McAuslane N; Walker S; Salek S
Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
[TBL] [Abstract][Full Text] [Related]
4. Integration of PKPD relationships into benefit-risk analysis.
Bellanti F; van Wijk RC; Danhof M; Della Pasqua O
Br J Clin Pharmacol; 2015 Nov; 80(5):979-91. PubMed ID: 25940398
[TBL] [Abstract][Full Text] [Related]
5. Two approaches to incorporate clinical data uncertainty into multiple criteria decision analysis for benefit-risk assessment of medicinal products.
Wen S; Zhang L; Yang B
Value Health; 2014 Jul; 17(5):619-28. PubMed ID: 25128056
[TBL] [Abstract][Full Text] [Related]
6. Regulatory requirements and optimization of multiple criteria decision analysis to quantify the benefit-risk assessment of medical devices.
Su G; Deng D
Expert Rev Med Devices; 2023 Apr; 20(4):273-281. PubMed ID: 36896851
[TBL] [Abstract][Full Text] [Related]
7. The identification of benefit in medical intervention: an overview and suggestions for process.
Stang PE; Pham SV; Kinchen K; Raff SB; Mussen F; Gondek K
Am J Ther; 2008; 15(5):495-503. PubMed ID: 18806527
[TBL] [Abstract][Full Text] [Related]
8. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
9. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
Maro JC; Brown JS
Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
[TBL] [Abstract][Full Text] [Related]
10. Food safety: risk assessment methodology and decision-making criteria.
Brock WJ; Rodricks JV; Rulis A; Dellarco VL; Gray GM; Lane RW
Int J Toxicol; 2003; 22(6):435-51. PubMed ID: 14680991
[TBL] [Abstract][Full Text] [Related]
11. A case study using the PrOACT-URL and BRAT frameworks for structured benefit risk assessment.
Nixon R; Dierig C; Mt-Isa S; Stöckert I; Tong T; Kuhls S; Hodgson G; Pears J; Waddingham E; Hockley K; Thomson A
Biom J; 2016 Jan; 58(1):8-27. PubMed ID: 25619173
[TBL] [Abstract][Full Text] [Related]
12. Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
Mt-Isa S; Ouwens M; Robert V; Gebel M; Schacht A; Hirsch I
Pharm Stat; 2016 Jul; 15(4):324-32. PubMed ID: 25981683
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Benefit-Risk Assessment Methods for Prospective Monitoring of Newly Marketed Drugs: A Simulation Study.
Gagne JJ; Najafzadeh M; Choudhry NK; Bykov K; Kahler KH; Martin D; Rogers JR; Schneeweiss S
Value Health; 2015 Dec; 18(8):1057-62. PubMed ID: 26686791
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive approach to benefit-risk assessment in drug development.
Sarac SB; Rasmussen CH; Rasmussen MA; Hallgreen CE; Søeborg T; Colding-Jørgensen M; Christensen PK; Thirstrup S; Mosekilde E
Basic Clin Pharmacol Toxicol; 2012 Jul; 111(1):65-72. PubMed ID: 22356197
[TBL] [Abstract][Full Text] [Related]
15. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
Angelis A; Kanavos P
Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
[TBL] [Abstract][Full Text] [Related]
16. Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature.
Kürzinger ML; Douarin L; Uzun I; El-Haddad C; Hurst W; Juhaeri J; Tcherny-Lessenot S
Ther Adv Drug Saf; 2020; 11():2042098620976951. PubMed ID: 33343857
[TBL] [Abstract][Full Text] [Related]
17. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
[TBL] [Abstract][Full Text] [Related]
18. A quantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis.
Mussen F; Salek S; Walker S
Pharmacoepidemiol Drug Saf; 2007 Jul; 16 Suppl 1():S2-S15. PubMed ID: 17546573
[TBL] [Abstract][Full Text] [Related]
19. Benefit-risk analysis : a brief review and proposed quantitative approaches.
Holden WL
Drug Saf; 2003; 26(12):853-62. PubMed ID: 12959629
[TBL] [Abstract][Full Text] [Related]
20. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.
Lynd LD; Najafzadeh M; Colley L; Byrne MF; Willan AR; Sculpher MJ; Johnson FR; Hauber AB
Value Health; 2010; 13(4):411-7. PubMed ID: 19744297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
